West Pharmaceutical Services (NYSE:WST) Issues FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 6.000-6.200 for the period, compared to the consensus earnings per share estimate of 7.430. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Stock Performance

NYSE WST traded down $117.20 on Thursday, hitting $205.08. The stock had a trading volume of 3,721,251 shares, compared to its average volume of 560,491. The company’s 50-day moving average is $332.39 and its two-hundred day moving average is $315.13. The stock has a market cap of $14.85 billion, a price-to-earnings ratio of 30.45, a P/E/G ratio of 19.31 and a beta of 1.01. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a one year low of $201.82 and a one year high of $408.88.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, beating the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. On average, analysts expect that West Pharmaceutical Services will post 6.67 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, February 11th. Investors of record on Friday, February 7th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.41%. The ex-dividend date of this dividend was Friday, February 7th. West Pharmaceutical Services’s payout ratio is currently 12.46%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wolfe Research initiated coverage on West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Bank of America boosted their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, December 13th. StockNews.com upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Tuesday. UBS Group upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $350.00 to $390.00 in a report on Thursday, December 12th. Finally, Citigroup started coverage on shares of West Pharmaceutical Services in a research note on Wednesday, January 8th. They set a “buy” rating and a $400.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $403.75.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.